MREO

Mereo Biopharma Group plc focuses on developing therapies for rare diseases, particularly those with limited treatment options. The company acquires late-stage clinical assets that have been deprioritized by larger pharmaceutical companies and collaborates with partners to advance these therapies. Mereo retains commercial rights in Europe for some products while partnering with other firms for development and commercialization in other regions. Its operations involve close collaboration with patients, healthcare systems, and industry stakeholders to navigate the complexities of drug development.